Document Detail

Drug therapy during labor and delivery, part 2.
MedLine Citation:
PMID:  16754739     Owner:  NLM     Status:  MEDLINE    
PURPOSE: The drug therapy of common conditions and complications during labor and delivery and the fetal and neonatal effects of this therapy are examined. SUMMARY: The pharmacologic therapy of common conditions that occur in labor and delivery primarily involves oxytocin and prostaglandins for cervical ripening and labor induction and systemic and regional narcotic analgesics for pain. Because most medications used in women during labor and delivery do not have Food and Drug Administration-approved labeling, pharmacists should understand the benefits and limitations of medications used in the mother. Although induction and augmentation of labor and the control of pain often require drug therapy, other, less frequent, complications may occur in labor. Drug therapies for these complications include anti-infective agents to treat maternal infection and prevent neonatal diseases; antiretrovirals to reduce perinatal HIV-1 transmission from the mother to the fetus; corticosteroids to prevent fetal lung immaturity; antihypertensives to treat preeclampsia; anticonvulsants to treat eclampsia; antibiotics to prolong pregnancy and improve neonatal outcomes after premature rupture of the membranes; tocolytics for premature labor; and oxytocin, ergot alkaloids, and prostaglandin analogues for postpartum hemorrhage. The fetal and neonatal effects of therapy for the conditions that occur during labor and delivery are usually benign, but significant morbidity and mortality involving the mother, the fetus, and the newborn are ever-present risks. CONCLUSION: Awareness of the conditions and complications requiring drug therapy during labor and delivery will allow hospital pharmacists to make knowledgeable decisions about the rapid accessibility of critical medications in the labor and delivery unit.
Gerald G Briggs; Stephanie R Wan
Related Documents :
11116239 - Changes in maternal lipid peroxidation levels and antioxidant enzymatic activities befo...
10694339 - Effective diminution of amniotic prostaglandin production by selective inhibitors of cy...
17091409 - Prevention of postpartum hemorrhage by uterotonic agents: comparison of oxytocin and me...
8106119 - Spinal cord dynorphin: positive region-specific modulation during pregnancy and parturi...
15506559 - Choosing calcium channel blockers for pregnant women with paroxysmal supraventriclar ta...
16776629 - Cardiac troponin t and amino-terminal pro-natriuretic peptide concentrations in fetuses...
8106939 - Registration of fetal behaviour in multiple pregnancy.
6174849 - Neural tube defects in new south wales: management and preventive policies, 1965-1980.
19103279 - The safety of conception occurring shortly after methotrexate treatment of an ectopic p...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  63     ISSN:  1079-2082     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-06-06     Completed Date:  2006-10-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1131-9     Citation Subset:  IM    
Women's Pavilion, Miller Children's Hospital, Long Beach Memorial Medical Center, Long Beach, CA 90806, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analgesia, Obstetrical / adverse effects
Cervical Ripening / drug effects
Eclampsia / drug therapy
Fetus / drug effects*
Labor, Induced
Obstetric Labor Complications / drug therapy*
Obstetric Labor, Premature
Postpartum Hemorrhage / prevention & control
Pre-Eclampsia / drug therapy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for brea...
Next Document:  Managing hypertension in patients with type 2 diabetes mellitus.